# US 2010/0061933 A1 · Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0061933 A1
- Document ID: US20100061933A1
- Status: Published application
- Kind: A1
- Application number: 12/311,960
- Filed: 2007-10-19
- Published: 2010-03-11
- Earliest claimed: 2006-10-20
- Inventors: Naoki Kimura
- Web page: https://patentgrep.com/patent/US20100061933A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.

## Claims

### Claim 1

An anti-HB-EGF antibody having an internalizing activity.

### Claim 2

An anti-HB-EGF antibody to which a cytotoxic substance is attached.

### Claim 3 (depends on 2)

The antibody according to claim 2, having an internalizing activity.

### Claim 4

An anti-HB-EGF antibody having an ADCC activity or a CDC activity.

### Claim 5 (depends on 1)

The antibody according to claim 1, further having a neutralizing activity.

### Claim 6

An antibody selected from the following [1] to [13]:
[1] an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 14 as CDR1, the amino acid sequence of SEQ ID NO: 16 as CDR2, and the amino acid sequence of SEQ ID NO: 18 as CDR3;
[2] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO: 20 as CDR1, the amino acid sequence of SEQ ID NO: 22 as CDR2, and the amino acid sequence of SEQ ID NO: 24 as CDR3;
[3] an antibody comprising the heavy chain according to [1] and the light chain according to [2];
[4] an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 26 as CDR1, the amino acid sequence of SEQ ID NO: 28 as CDR2, and the amino acid sequence of SEQ ID NO: 30 as CDR3;
[5] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO: 32 as CDR1, the amino acid sequence of SEQ ID NO: 34 as CDR2, and the amino acid sequence of SEQ ID NO: 36 as CDR3;
[6] an antibody comprising the heavy chain according to [4] and the light chain according to [5];
[7] an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 76 as CDR1, the amino acid sequence of SEQ ID NO: 77 as CDR2, and the amino acid sequence of SEQ ID NO: 78 as CDR3 (HE-39 Heavy chain);
[8] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO: 79 as CDR1, the amino acid sequence of SEQ ID NO: 80 as CDR2, and the amino acid sequence of SEQ ID NO: 81 as CDR3 (HE-39 Light chain-1);
[9] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO: 82 as CDR1, the amino acid sequence of SEQ ID NO: 83 as CDR2, and the amino acid sequence of SEQ ID NO: 84 as CDR3 (HE-39 Light chain-2);
[10] an antibody comprising the heavy chain according to [7] and the light chain according to [8];
[11] an antibody comprising the heavy chain according to [7] and the light chain according to [9];
[12] an antibody having the activity equivalent to that of the antibody according to any of [1] to [11]; and
[13] an antibody that binds an epitope that is the same as the epitope bound by the antibody according to any of [1] to [12].

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the antibody according to claim 1.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a cytotoxic substance attached to the antibody according to claim 1.

### Claim 9 (depends on 7)

The pharmaceutical composition according to claim 7, which is a cell proliferation inhibitor.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, which is an anti-cancer agent.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the cancer is pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, a brain tumor, or a hematological cancer.

### Claim 12

A method of delivering a cytotoxic substance into a cell by means of an anti-HB-EGF antibody.

### Claim 13

A method of inhibiting cell proliferation with a cytotoxic substance attached to an anti-HB-EGF antibody.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the cell is a cancer cell.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the cytotoxic substance is a chemotherapeutic agent, a radioactive substance, or a toxic peptide.

### Claim 16

Use of an anti-HB-EGF antibody for transporting a cytotoxic substance into a cell.

### Claim 17

Use of an anti-HB-EGF antibody having an internalizing activity for inhibiting cell proliferation.

### Claim 18 (depends on 17)

The use according to claim 17, wherein the anti-HB-EGF antibody further comprises a neutralizing activity.

### Claim 19 (depends on 18)

The use according to claim 18, wherein the anti-HB-EGF antibody further comprises an antibody-dependent cell-mediated cytotoxicity (ADCC) or a complement-dependent cytotoxicity (CDC).

### Claim 20 (depends on 16)

The use according to claim 16, wherein the cell is a cancer cell.

### Claim 21 (depends on 16)

The use according to claim 16, wherein a cytotoxic substance is attached to the anti-HB-EGF antibody.

### Claim 22

A method of producing a pharmaceutical composition comprising the steps of:
(a) providing an anti-HB-EGF antibody;
(b) determining whether the antibody of (a) has an internalizing activity;
(c) selecting an antibody that has an internalizing activity; and
(d) attaching a cytotoxic substance to the antibody selected in (c).

### Claim 23 (depends on 22)

The method according to claim 22, wherein the pharmaceutical composition is an anti-cancer agent.

### Claim 24

A method of diagnosing cancer using an anti-HB-EGF antibody.

### Claim 25 (depends on 24)

The method according to claim 24, comprising using an anti-HB-EGF antibody to which a labeling substance is attached.

### Claim 26 (depends on 24)

The method according to claim 24, wherein an intracellularly incorporated anti-HB-EGF antibody is detected.

### Claim 27

An anti-HB-EGF antibody to which a labeling substance is attached.

### Claim 28 (depends on 27)

The antibody according to claim 27, having an internalizing activity.
